• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $3 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-6 Mln

Qualigen Therapeutics Inc. (QLGN) Share Price

$0.47

As on 28-Feb-2024 15:54 EST

up-down-arrow $-0.02-4.12%

  • Prev Close info

    $0.49

  • Day's Openinfo

    $0.48

  • Today's Highinfo

    $0.51

  • Today's Lowinfo

    $0.47

  • Today's Volumeinfo

    80,533

  • 52 Week rangeinfo

    $0.45 - 1.38

Please wait...

Qualigen Therapeutics Inc. (QLGN) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Qualigen Therapeutics (QLGN)
-14.55 -5.43 -30.98 -58.41 -75.74 -68.89 --
S&P BSE Sensex
0.09 2.27 9.60 21.95 13.77 15.03 13.17
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 28-Feb-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Qualigen Therapeutics (QLGN)
-57.33 -87.95 -64.45 -28.72 -71.85 -81.62 -87.85
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Qualigen Therapeutics Inc. (QLGN) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Qualigen Therapeutics Inc. (QLGN)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Qualigen Therapeutics Inc. (QLGN)

        President, COO, CEO & Chairman

        Mr. Michael S. Poirier

        Senior VP & Chief Medical Officer

        Dr. Tariq Arshad M.B.A., M.D.

        Headquarters

        Carlsbad, CA

        FAQs for Qualigen Therapeutics Inc. (QLGN)

        The total asset value of Qualigen Therapeutics Inc. (QLGN) stood at $ 10 Mln as on 30-Sep-23

        The share price of Qualigen Therapeutics Inc. (QLGN) is $0.47 (NASDAQ) as of 28-Feb-2024 15:54 EST. Qualigen Therapeutics Inc. (QLGN) has given a return of -75.74% in the last 3 years.

        Qualigen Therapeutics Inc. (QLGN) has a market capitalisation of $ 3 Mln as on 28-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Qualigen Therapeutics Inc. (QLGN) is 0.35 times as on 28-Feb-2024, a -0.88% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Qualigen Therapeutics Inc. (QLGN) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Qualigen Therapeutics Inc. (QLGN) and enter the required number of quantities and click on buy to purchase the shares of Qualigen Therapeutics Inc. (QLGN).

        Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. Address: 2042 Corte Del Nogal, Carlsbad, CA, United States, 92011

        The CEO & director of Mr. Michael S. Poirier. is Qualigen Therapeutics Inc. (QLGN), and CFO & Sr. VP is Dr. Tariq Arshad M.B.A., M.D..

        The promoters of Qualigen Therapeutics Inc. (QLGN) have pledged 0% of the total equity as on Sep-23.

        Qualigen Therapeutics Inc. (QLGN) Ratios
        Return on equity(%)
        --
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Qualigen Therapeutics Inc. (QLGN) was $-6 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $2.89 Mln
        • Revenue (TTM)revenue-information $4.41 Mln
        • Earnings (TTM) earning-information $-6.37 Mln
        • Cash date-information $2.07 Mln
        • Total Debt info $0.83 Mln
        • Insider's Holding 11.27%
        • Liquidity liquidity Moderate
        • 52 Week range week-range $0.45 - 1.38
        • Shares outstanding share-outstanding 5,181,060
        • 9 Years Aggregate:

          CFO: $-86.62 Mln

          EBITDA: $-157.89 Mln

          Net Profit: $-10,133,147.11 Mln

        About The Company

        • IPO Date 24-Jun-2015
        • President, COO, CEO & Chairman Mr. Michael S. Poirier
        • Senior VP & Chief Medical Officer Dr. Tariq Arshad M.B.A., M.D.
        • Listing key-listing NASDAQ: QLGN
        • Country United States
        • Headquarters headquarters Carlsbad, CA
        • Website website https://www.qualigeninc.com
        • Business

          Qualigen Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a patent-protected rapid, onsite immunoassay...  testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, an oligonucleotide-based drug candidate to treat various nucleolin-expressing cancers, including liquid and solid tumors; QN-165, a drug candidate for the potential broad-spectrum treatment of infectious diseases, such as COVID-19; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and selective target antigen removal system, a therapeutic device to remove circulating tumor cells, viruses, inflammation factors, and immune checkpoints. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California. Address: 2042 Corte Del Nogal, Carlsbad, CA, United States, 92011  Read more

        share-fund-plan-icon